Prostate- and metastases-directed radiotherapy in de novo low-volume metastatic prostate cancer
Combined PDRT and MDRT in addition to standard of care in patients with de novo LVmPC is feasible, well tolerated, and associated with promising biochemical control. Further prospective studies with larger patient cohorts integrating PSMA-PET/CT and other risk stratification factors are warranted to better define which patient subgroups benefit most from additional radiotherapy.
Authors
- Magdalena Görtz (ORCID: https://orcid.org/0000-0001-6195-1609)
- L. Wessel
- Jakob Liermann (ORCID: https://orcid.org/0000-0002-1445-1940)
- Stefanie Zschaebitz
- Felix H. Englert
- Jan-Hendrik Bolten (ORCID: https://orcid.org/0000-0002-5074-2905)
- Jürgen Debus (ORCID: https://orcid.org/0000-0002-6411-4811)
- Johannes Huber (ORCID: https://orcid.org/0000-0001-7243-8958)
- Fabian Weykamp (ORCID: https://orcid.org/0000-0003-1731-7090)
- Erik Winter (ORCID: https://orcid.org/0000-0001-7646-3026)
- Christoph A. Fink (ORCID: https://orcid.org/0000-0001-8222-2288)
- David Neugebauer
- Justus Valentini (ORCID: https://orcid.org/0009-0002-6764-5842)
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Heidelberger Institut für Radioonkologie (DE)
- National Center for Tumor Diseases (DE)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1016/j.ctro.2025.101072
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00